newsfilter
← Latest News
Business Wire·

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to